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ABSTRACT  
 
Purpose: This study was undertaken to determine the feasibility of perioperative high-
dose-rate brachytherapy (PHDRB) as an accelerated boost in patients with pediatric 
sarcomas. 
 
Methods and materials: Five pediatric patients (ages 7–16) with soft tissue sarcomas 
(STS) or soft tissue recurrences of previously treated osteosarcomas were treated with 
surgical resection and PHDRB (16–24 Gy) for R0-R1 resections. Patients with STS and 
osteosarcomas received 27 Gy and 45 Gy of EBRT postoperatively. 
 
Results: After a median follow-up of 27 months (range, 12–50) all the patients remain 
locally controlled. Only 1 patient developed regrowth of pulmonary metastases and died 
of distant disease at 16 months. 
 
Conclusions: The use of PHDRB is safe in the short-term in this pediatric population. 
Only 1 patient suffered a partial wound dehiscence that may not be entirely related to 
PHDRB. Patients withrecurrent osteosarcomas canbe treatedinafashion similartotheir 
adultsoft tissuecounterpartsand avoid limb amputation. Younger patients with STS may 
achieve local control and prevent growth retardation with a combination of PHDRB and 
moderate doses of EBRT.  
 
Keywords: Pediatric; Soft tissue sarcomas; Osteosarcoma; Perioperative; High dose 
rate; Brachytherapy 
INTRODUCTION 
 
Conventional EBRT is an integral part of the treatment of most children and adolescents 
with soft tissue sarcomas (STS). However, in the growing child, potential growth 
retardation and deformity associated with the use of EBRT are a serious concern that 
can limit its use (1). 
 
Radiation techniques that improve the therapeutic ratio are especially important for 
these growing individuals. Intraoperative radiation boosting techniques have the 
advantage of direct tumor bed localization and displacement of radiosensitive structures, 
where possible, away from the area irradiated. The majority of worldwide experience 
has been with LDR manual brachytherapy, and this modality has produced acceptable 
local control and complication rates (2–4). The major disadvantages with this modality 
have been the issue of radiation protection, the need to immobilize and sedate the 
younger children during treatment, and the psychological trauma associated with 
separation from the parents. The advent of remote-controlled LDR, PDR, and HDR 
machines as well as the development of intraoperative high-dose-rate brachytherapy 
(IOHDR) and intraoperative electron beam radiotherapy (IOERT) has eliminated 
radiation exposure hazards to the patient’s family and medical personnel. 
 
IOHDR and IOERT have been used in pediatric patients (5–7). However, high-dose 
(≥15 Gy) IOERT has been associated with clinically significant toxicity in late-reacting 
tissues such as vessels and nerves present in the surgical bed (8). As a consequence, 
these normal tissues at risk of harboring metastatic deposits may remain undertreated 
for fear of long-term toxicity, and this reluctance to treat may ultimately lead to 
treatment failure. 
 
High-dose-rate (HDR) brachytherapy alone has been used with success in the younger 
patients with more chemoresponsive tumors (e.g., rhabdomyosarcoma) in whom the 
smaller postchemotherapy tumor volume can be encompassed with an interstitial or 
intracavitary implant, eliminating the need for additional EBRT (9). However, older 
children with more extensive tumors cannot be treated with brachytherapy alone and 
may require EBRT. 
 
For patients requiring EBRT, we designed a treatment protocol that involved using 
perioperative HDR brachytherapy (PHDRB) and postoperative low-to-moderate dose 
EBRT (27–45 Gy). The outcomes for patients treated by PHDRB are reported in this 
article. 
 
 
 
METHODS AND MATERIALS 
 
From June 2000 to August 2003, 5 patients with pediatric sarcomas (4 boys, 1 girl; ages 
ranging from 7 to 16 years; median, 11.0 years) were treated with PHDRB and 
conservative surgery. The PHDRB dose was 4 Gy b.i.d. (interfraction interval of at least 
6 h) X 6 (24 Gy total dose). Radiation treatment was completed with EBRT (27–45 Gy 
in 15–25 treatments, 1.8 Gy daily fractions) 4–5 weeks after the surgical procedure. The 
lower dose was used for the younger patients with soft tissue sarcomas, and the higher 
dose was used in the older patients with soft tissue recurrences of osteosarcomas. Total 
radiation doses equivalent to standard fractionation regimens delivered with 2 Gy daily 
fractions and calculated with the linear quadratic formulation without time correction 
(i.e., BED = nd[1+d/(α/β)]) (10) are shown in Fig. 1. 
 
The surgical and the radiation oncology teams used the preoperative physical and 
imaging, surgical findings, frozen sections where necessary, and gross examination of 
the surgical specimen to jointly determine the area to be implanted, although in most 
cases the entire surgical bed was implanted. 
 
 
Brachytherapy technique 
 
Traditional implant guidelines recently released by the American Brachytherapy Society 
were generally followed (11). The CTV was covered with a set of plastic catheters 
placed as near to parallel as possible at 1.0–1.5 cm intervals with a margin of 1 cm in all 
directions. A single plane implant array was the most frequently used. The lateral 
margins were treated with additional catheters extending beyond the CTV. The 
longitudinal margins were added by setting the distal and proximal ends of the catheters 
at 1.5–2.0 cm beyond the skin incision. Catheters were inserted no more than 5 mm into 
the tumor bed to avoid underdosage of the surgical surface. This maneuver avoided 
catheter displacement and resulted in improved geometry. In cases in which the 
catheters could not be inserted below the surface, resorbable sutures were used to secure 
the catheters onto the surgical surface. If necessary, gelfoam or muscle flaps no more 
than 5 mm thick were interposed between the catheter plane and radiosensitive 
structures. Finally, catheters were attached at the skin exit points with plastic buttons 
and silk sutures. Once the implant was performed, the surgical team proceeded with the 
closure or, if necessary, with the reconstruction of the surgical defect with regional or 
microvascular free flaps. 
 
 
3D dosimetry guidelines 
 
A CT scan for verification was performed during the first 48 h after surgery, once the 
patient was in stable condition and ready for transportation. The CT study was 
transferred to the Radiation Treatment Planning System for dosimetry. The treatment 
planning process followed the Paris System with manual optimization for each of the 
CT slices. Additional rules included that the CTV be encompassed by the 4 Gy isodose 
line, defined as the minimum tumor dose (MTD) isodose line as per the ICRU No. 58 
recommendations (12). An MTD to mean central dose (MCD) ICRU No. 58 ratio of not 
less than 70% was accepted, provided that the volume encompassed by the 6 Gy isodose 
(V150) was not greater than 50% of the volume encompassed by the 4 Gy isodose 
(V100). Automatic optimization algorithms provided by the Treatment Planning System 
were not allowed. Once the treatment plan was approved, it was transferred to the 
afterloader unit control console where the dwell positions and treatment times were 
double-checked by the radiation technologist. Brachytherapy delivery began 3–6 days 
after surgery (median, 5 days). The rest of the brachytherapy parameters are detailed in 
Table 1. 
 
 
 
External radiation 
 
All patients underwent customized immobilization and virtual CT simulation before 
starting external beam therapy. 
  
The CTV included the presurgical gross tumor extent with 5 cm margins in the direction 
of the body axis and 2–3 cm laterally as well as the entire surgical scar. 
 
 
Outcome analysis 
 
Local failure was defined as the occurrence of tumor regrowth in the area treated with 
brachytherapy or in an adjacent region (i.e., recognition failure). Any other failure in the 
anatomical region implanted but not in close continuity with the implanted area was 
considered as regional, and any failure elsewhere was considered distant failure. 
 
Early toxicities were defined as those occurring from the date of surgery to 60 days after 
the completion of the treatment. Toxicities were classified as late if they occurred more 
than 60 days after the completion of the treatment. Toxicities were documented 
according to the Radiation Therapy Oncology Group (RTOG) morbidity scoring 
criteria. 
 
 
 
RESULTS 
 
After a median follow-up of 27 months (range, 12–50 months), all the patients remained 
locally controlled. In addition, 4 of 5 patients are alive and without evidence of disease. 
The other patient, with stage IV condroblastic osteosarcoma developed regrowth of 
pulmonary metastases at 9 months and died at 16 months without evidence of 
locoregional failure. Patient characteristics and outcome are shown in Tables 2 and 3. 
The following cases illustrate the possible usefulness of PHDRB in these specific 
disease situations. 
  
 
Case No. 1 (F.J.R.R.) 
 
This 11-year-old boy had been initially treated in 1999 with preoperative chemotherapy, 
surgery, and adjuvant chemotherapy according to the T-10 protocol (high dose 
methotrexate, bleomycin, cyclophosphamide, dactinomycin, cisplatin, and doxorubicin). 
The patient developed a wound dehiscence and multiple episodes of allograft infection 
during the administration of the adjuvant chemotherapy regimens, which led to several 
reoperations including two allograft replacements. He developed a local relapse 
involving the tibial allograft with soft tissue extension into the anterior aspect of the 
knee 14 months after the primary surgery. The MRI showed a lesion of 3.5 cm in 
diameter with some satellite nodules. He was operated on with a marginal resection of 
the lesion leaving close margins (1 mm). Three catheters were inserted into the deepest 
aspect of the tumor bed. The patient developed a partial wound dehiscence and surgical 
bed infection that led to the placement of a knee prosthesis 11 months later. The patient 
is alive and free of disease 50 months later and walks with the aid of crutches. 
Case No. 2 (J.F.S.) 
 
This 16-year-old boy had been initially treated in 1999 with preoperative chemotherapy, 
surgery, and adjuvant chemotherapy according to the T-10 protocol in another 
institution. He developed pulmonary metastases and a local relapse in the poplyteal 
fossa 10 months after the primary surgery. The MRI showed a bulky soft tissue mass of 
8.0 cm in diameter displacing the poplyteal vessels. Marginal resection of the lesion left 
close margins at the level of the poplyteal vessels (7 mm). Three catheters were inserted 
into the deepest aspect of the tumor bed. The patient died 16 months later after regrowth 
of pulmonary metastases and new onset brain metastases, although the tumor was 
locally controlled and the patient was fully ambulant. 
 
 
Case No. 3 (C.T.B.) 
 
This 11-year old girl presented with a 10 cm lump deep in the anterior compartment of 
the distal thigh, in proximity to the femoral bone. A conservative resection was carried 
out, and four afterloading catheters were placed onto the anterior aspect of the femur 
due to the concerns of inadequate resection margins at that level. The final pathology 
report revealed close margins (6 mm) at that level, and adding PHDRB and low-dose 
EBRT was recommended. No adjuvant chemotherapy was given. She is alive with fully 
preserved limb function and without evidence of disease at 34 months after surgery. 
 
 
Case No. 4 (A.L.L.) 
 
This 9-year old boy presented with a 4.5 cm mass infiltrating the pterygoid space in the 
vicinity of the carotid vessels and attached to the pterygoid process in the left side. He 
was initially treated with one course of neoadjuvant chemotherapy without remarkable 
response. A limited surgical resection left positive margins in the pterygoid process. 
Four catheters were placed for PHDRB. No adjuvant chemotherapy was given. The 
patient is alive with fully preserved oral aperture and masticatory function and without 
evidence of disease 12 months after surgery. 
 
 
Case 5 (D.F.O.) 
 
This 7-year old boy presented with a 1-cm mass involving the synovial capsule in the 
lateral aspect of the elbow. An excisional biopsy at another hospital demonstrated an 
unsuspected undifferentiated sarcoma. A reoperative procedure was recommended, and 
4 catheters were left in place for PHDRB. Although the surgical specimen obtained 
demonstrated no tumor, complementing the surgical procedure with adjuvant PHDRB 
and low-dose EBRT was recommended due to the concerns about contamination of the 
surgical bed during the primary procedure. No adjuvant chemotherapy was given. Dose 
volume histograms revealed that the D10 (10% of the volume of interest that receives 
the higher dose) of the distal (2.35 Gy) and proximal (3.00 Gy) growth plates of the 
elbow joint were below the prescription isodose of 4 Gy. The patient is alive with fully 
preserved elbow motion and without evidence of disease 12 months after surgery. 
 
 
DISCUSSION 
 
Comparison among different brachytherapy series on pediatric STS is especially 
difficult due to the small number of patients treated, the different brachytherapy 
modalities used (low dose rate, pulsed dose rate, fractionated and intraoperative high 
dose rate) and the use or not of EBRT. In addition, the inclusion of a relatively large 
percentage of patients with rhabdomyosarcoma, a more chemo- and radio-responsive 
pediatric sarcoma, may contaminate the final results obtained. 
 
Dose guidelines for pediatric non-rhabdomyosarcoma STS are not clearly defined. We 
decided to treat the 3 patients of this disease category (patient 3, 4, and 5) with 24 Gy of 
PHDRB followed by 27 Gy of EBRT (Fig. 1). According to the LQ model (10) this is 
roughly equivalent to a total MTD of 55 Gy delivered with standard fractionation. 
Similar total doses had already been used in the management of pediatric STS by 
several institutions with excellent local control results (4, 13). The Institute Gustave 
Roussy, France (13), treated 127 children (mostly with STS) with LDR brachytherapy 
(0.4–0.6 Gy/h) from 1972 to 1990. Brachytherapy doses were 45–65 Gy when used as a 
sole modality and 15–25 Gy when used as a boost. Patients who received brachytherapy 
as primary treatment had local control of 81%. 
 
The addition of supplemental EBRT is also a matter of controversy due to the fear of 
long-term complications related to the use of this radiation modality in younger children 
(1). Nag et al. (9) from The Ohio State University published their results on 12 children 
with STS (9 rhabdomyosarcomas) with a median age of 18 months at diagnosis. 
Teletherapy was avoided in this young patient population. HDR brachytherapy was 
delivered in 3 Gy fractions twice a day to a total dose of 36 Gy in 8 days. Results 
showed a 6 year actuarial local control of 91%. However, the use of brachytherapy 
alone raises the concern of decreased control rates due to the emergence of marginal 
failures, especially in non-rhabdomyosarcoma STS. Goodman et al. (7) reported the 
experience of the MSKCC with IOHDR in pediatric patients (mostly neuroblastoma, 
rhabdomyosarcoma, and Ewing’s/PNET). A total of 66 pediatric patients with a median 
age of 7 years were reviewed. Fifty-three percent of the patients were treated for 
recurrent disease. Twentynine patients (44%) received IOHDR (median, 12 Gy) and 
EBRT. The 2-year local control rate was 56%. Postoperative EBRT significantly 
improved the 2-year local control rate from 29% to 83% (p = 0.002). According to the 
authors, the benefit of adjuvant EBRT after brachytherapy may be related to a dose–
response effect or better coverage of microscopic residual disease with the larger 
treatment volumes used for EBRT. In a similar approach, Nag et al. (5) combined a 
single dose of 10–12.5 Gy HDR given intraoperatively with modest doses (27–36 Gy) 
of teletherapy given postoperatively. Six children treated with this protocol are currently 
alive, and five are without evidence of disease after 40 months (range, 22–62 months). 
 
Dose guidelines for pediatric osteosarcoma are not available. The use of adjuvant 
radiation therapy has been largely abandoned due to the extremely low local failure 
rates after neoadjuvant chemotherapy and surgical resection. Therefore, we extrapolated 
the National Comprehensive Cancer Center recommendations for adult STS with 
positive margins that call for 20 Gy of brachytherapy followed by 50 Gy of EBRT and 
treated the 2 patients of this disease category (patients 1 and 2) with 24 Gy of PHDRB 
followed by 45 Gy of EBRT (Fig. 1). 
 
CONCLUSION 
 
The use of PHDRB is a feasible alternative in those patients in whom extensive surgery 
is inadvisable, and therefore more limited surgery is attempted to prevent long-term 
disability. The initial results show that a reasonable local control and long-term disease-
free survival can be achieved, despite a lower EBRT dose in those patients with 
nonrhabdomyosarcoma STS. In addition, those patients with recurrent osteosarcomas 
can attain long-term local control and avoid amputation. Although some major centers 
favor the use of HDR brachytherapy alone in the pediatric population, we preferred to 
use PHDRB in combination with EBRT due to preliminary data from The Memorial 
Sloan-Kettering Cancer Center (14) suggesting a trend in favor of brachytherapy boost 
combined with EBRT in patients with positive resection margins. Toxicity directly 
associated with radiation therapy has been modest even with the use of total doses that 
may exceed effective adult sarcoma doses in those patients treated for recurrent 
osteosarcoma. We have only observed one case of wound dehiscence that can be 
regarded as multifactorial in origin in view of the bizarre previous history. Long-term 
results in terms of local control and growth preservation must wait until the patients 
stop growing after puberty. 
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Table 1. Brachytherapy parameters 
Number of catheters  
Median 4 
Range 3-4 
Surgery to brachytherapy gap (days)  
Median 5 
Range 3-6 
Brachytherapy duration (days)  
Median 3 
Range 3 
TV100 (cc)  
Median 33,3 
Range 13,0-86,6 
TV150 (cc)  
Median 12,6 
Range 4,8-35,1 
TV100 = Tissue volume encompassed by the 100% 
prescription isodose (4Gy). 
TV150 = Tissue volume encompassed by the 150% 
prescription isodose (6Gy).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2. Tumor and treatment characteristics 
Case 
no. Histology 
AJCC 
stage Age PHDRB site
Resection 
margins 
PHDRB 
dose 
EBRT 
dose 
1 Osteoblastic osteosarcoma Recurrent 11 
Poplyteal 
fossa 1 mm 24 Gy 45 Gy 
2 Condroblastic osteosarcoma Recurrent 16 
Poplyteal 
fossa 6 mm 24 Gy 45 Gy 
3 Synovial sarcoma IIa 11 Thigh 7 mm 24 Gy 27 Gy 
4 Fibrosarcoma Ib 9 Pterygoid fossa Positive 24 Gy 27 Gy 
5 Undifferentiated sarcoma IIb 7 Elbow Negative 24 Gy 27 Gy 
 
 
 
 
 
Table 3. Patient outcome 
Case 
no. Histology Complications 
Local 
control 
Distant 
metastases 
Survival 
(months) Status 
1 Osteoblastic osteosarcoma 
Wound dehiscence 
grade 4 Yes No 50+ NED 
2 Condroblastic osteosarcoma None Yes Yes 16 DOD 
3 Synovial sarcoma None Yes No 34+ NED 
4 Fibrosarcoma None Yes No 12+ NED 
5 Undifferentiated sarcoma None Yes No 12+ NED 
NED = Alive, no evidence of disease; DOD = Dead of disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Treatment scheme. 
 
